FDA decision nears on Aimmune's contested peanut allergy drug

If the Food and Drug Administration follows the advice of its outside advisers, the agency will within days grant the first-ever approval to a drug designed to make peanut allergy sufferers less likely to have a dangerous reaction.

Called Palforzia, the drug was developed by the California-based biotech Aimmune. It's in close competition with a French company called DBV Technologies, which should see the FDA decide on its patch-based peanut allergy treatment by August.